Study:
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
Rationale:
Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in
patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more
effective than clodronate or ibandronate in treating breast cancer.
Purpose:
This randomized phase III trial is studying zoledronate to see how well it works
compared to clodronate or ibandronate in treating women who have undergone surgery for stage
I, stage II, or stage III breast cancer.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic - Wooster 800-862-7798
George T. Budd, MD 216-444-6480
Clinical Trials Office - Cleveland Clinic Cancer Center at Fai 216-476-9362
George T. Budd, MD 216-444-6480
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Drug: clodronate disodium
Drug: ibandronate sodium
Drug: zoledronic acid |
Phase 3 |
Verified by
Southwest Oncology Group
January, 2010
Sponsored by: Southwest Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00127205
Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio 44122
United States
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Julie R. Gralow, MD.,
Robert B. Livingston, MD.,
James N. Ingle, MD.,
Carla I. Falkson, MD.,
Alexander H. G. Paterson, MD, FRCP, FACP, MBChB.,
Elizabeth C. Dees, MD.,
Mark J. Clemons, MD.,